Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
NCT04332991 · View on ClinicalTrials.gov ↗
Study Summary
ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hydroxychloroquine
Study Locations (20)
California
- UCSF Fresno — Fresno
- Ronald Reagan UCLA Medical Center — Los Angeles
- UC Davis Medical Center — Sacramento
- UCSF Medical Center — San Francisco
- Stanford University — Stanford
Massachusetts
- Massachusetts General Hospital — Boston
- Beth Israel Deaconess Medical Center — Boston
- Brigham and Women's Hospital — Boston
- Baystate Medical Center — Springfield
- St. Vincent's Hospital — Worcester
Colorado
- Medical Center of Aurora — Aurora
- University of Colorado Hospital — Aurora
- Denver Health Medical Center — Denver
- St. Joseph Hospital — Denver
Arizona
- University of Arizona — Tucson
Florida
- University of Florida — Gainesville
Kentucky
- University of Kentucky — Lexington
Louisiana
- University Medical Center — New Orleans
Maine
- Maine Medical Center — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2020-04-02 |
| Est. Completion | 2020-07-23 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04332991
The ClinicalTrials.gov registry entry for NCT04332991 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 1,948 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Coronavirus appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04332991 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Massachusetts, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04332991 about?
NCT04332991 is a clinical study titled "Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease". ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.
What is the current status of trial NCT04332991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 479 participants. The study started on 2020-04-02. Estimated completion is 2020-07-23.
What conditions does trial NCT04332991 study?
This clinical trial studies the following conditions: Coronavirus, SARS-CoV Infection, Acute Respiratory Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04332991?
The interventions under investigation include: Placebo (DRUG), Hydroxychloroquine (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04332991?
This trial is sponsored by Massachusetts General Hospital, which has 1,948 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04332991 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.